Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis

Abdelazim, Ibrahim A.; Abdelrazak, Khaled M.; Al-Kadi, Mohamed; Yehia, Ahmed; Faza, Mohannad Abu

doi:10.1007/s11657-014-0189-9

Cited by 7 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Selective estrogen receptor modulators (SERMs) were another class of anti-osteoporotic drug, which also reduce bone turnover and affect serum OC level in human[ 18 ]. Calcitonin reduces bone turnover, but its effect on serum OC is not clear.…”

Section: Discussionmentioning

confidence: 99%

The Use of Alendronate Is Associated with a Decreased Incidence of Type 2 Diabetes Mellitus—A Population-Based Cohort Study in Taiwan

Chan

Yang

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

PurposeBone remodeling has been linked to glucose metabolism in animal studies, but the results of human trials were inconclusive. Bisphosphonates may play a role in glucose metabolism through their impacts on bone remodeling enzymes. In this study, we aimed to examine the influence of alendronate usage on the incidence of type 2 diabetes mellitus (DM) among osteoporotic patients.MethodsA retrospective cohort study was designed to include osteoporotic patients without DM from a population-based cohort containing 1,000,000 subjects. Patients treated with alendronate (exposed group, N=1,011) were compared with those who received no treatment (age and gender matched non-exposed group, N=3,033). Newly diagnosed DM was identified from medical records by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9CM) code. The incidence of DM in both groups was calculated for comparison.ResultsThe non-exposed group had a significantly higher incidence of DM (Odds ratio 1.21, 95% confidence interval 1.03~1.41) when compared with the exposed group. In subgroup analysis, the DM risk reduction in exposed group was only significant among those younger than 65 years and those without hypertension or dyslipidemia. Patients who were prescribed alendronate more than or equal to 3 times had demonstrated a significant reduction in DM risk.ConclusionsOur study showed alendronate might yield a protective effect for incident DM. This effect became insignificant in patients with older age, dyslipidemia or hypertension. The underlying mechanism needs further exploration with prospective data for confirmation of the observed findings.

show abstract

Section: Discussionmentioning

confidence: 99%

The Use of Alendronate Is Associated with a Decreased Incidence of Type 2 Diabetes Mellitus—A Population-Based Cohort Study in Taiwan

Chan

Yang

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Gegenüber einer alleinigen Gabe von Kalzium und Vitamin D kam es nach 1-jähriger Therapie mit Raloxifen bei postmenopausalen Frauen zu einer signifikanten Zunahme der Knochendichte an LWS und Hüfte [1]. Auch Bazedoxifen führte bei postmenopausalen Frauen nach 2-jähriger Therapie zu einem signifikanten Anstieg der Knochendichte gegenüber Placebo an allen Messpunkten der Hüfte [3].…”

Section: Selektive öStrogenrezeptormodu-latorenunclassified

Individualisierte Therapie der Osteoporose

Harbeck

Lehnert

2016

Internist

View full text Add to dashboard Cite

Osteoporosis is the most common clinical disorder of bone metabolism. Treatment decisions should be made on an individual basis, taking into consideration the relative benefits and risks in different patient populations. Drug selection should be based on the form (primary/secondary) and severity of osteoporosis, age, sex, the specific contraindications and precautions for using the various available medications, and existing comorbidities.

show abstract

“…Osteoporosis is a skeletal disorder of low bone mass and microarchitectural deterioration of bone, leading to bone fragility and increased risk of fracture. 1 Osteoporosis affects more than 10 million U.S. adults aged 50 years or older. 2 About two million U.S. adults experience an osteoporotic or other low-or no-trauma fracture each year.…”

Section: Introductionmentioning

confidence: 99%

“…To further these aims, we conducted this systematic review to address the following questions: (1) What are the effects of long-term (>3 years) osteoporosis drug treatment versus control on risks of incident fractures and harms; (2) Do effects of long-term osteoporosis drug treatment vary as a function of patient, bone, or osteoporosis drug characteristics; (3) Among individuals receiving osteoporosis drug treatment to prevent fracture, what are the effects of continuing versus discontinuing treatment (i.e., osteoporosis drug holiday) on risks of incident fractures and harms; and (4) Do these outcomes of drug holidays vary as a function of patient, bone, or osteoporosis drug characteristics? ES-2…”

Section: Introductionmentioning

confidence: 99%

Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

Fink

MacDonald

Forte

et al. 2019

View full text Add to dashboard Cite

Purpose of ReviewTo summarize the effects of long-term osteoporosis drug treatment and of osteoporosis drug treatment discontinuation and holidays. Key Messages• Evidence on the effects of long-term osteoporosis drug treatment and drug continuation versus discontinuation is mostly limited to white, healthy, postmenopausal women. • Long-term alendronate reduces radiographic vertebral and nonvertebral fractures in women with osteoporosis; long-term zoledronate reduces vertebral and nonvertebral fractures in women with osteopenia or osteoporosis. • Long-term bisphosphonates may increase atypical femoral fractures and osteonecrosis of the jaw, although both are rare. • In women with osteoporosis, long-term raloxifene reduces vertebral fractures, but not hip or nonvertebral fractures, and increases venous thromboembolism. • Long-term oral hormone therapies reduce hip and clinical fractures but increase multiple serious harms. • Evidence is insufficient about the effects of long-term denosumab, risedronate, ibandronate, teriparatide, and abaloparatide on fractures and harms. • Continuing bisphosphonates after 3-5 years versus discontinuation reduces some measures of vertebral fractures, but not nonvertebral fractures.

show abstract

Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis

Abstract: Raloxifene appears to be an effective, well-tolerated option for treating osteoporosis in Kuwaiti postmenopausal women, suitable for long-term use.

Cited by 7 publications

References 15 publications

The Use of Alendronate Is Associated with a Decreased Incidence of Type 2 Diabetes Mellitus—A Population-Based Cohort Study in Taiwan

The Use of Alendronate Is Associated with a Decreased Incidence of Type 2 Diabetes Mellitus—A Population-Based Cohort Study in Taiwan

Individualisierte Therapie der Osteoporose

Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

Contact Info

Product

Resources

About